Long-term outcomes of LDR-brachytherapy for localized prostate cancer
IntroductionThis retrospective study aims to evaluate the long-term efficacy and urinary toxicity of LDR-brachytherapy for localized prostate cancer.Materials and methods235 primary prostate cancer patients treated with LDR-brachytherapy and subsequently followed up in our center were included in th...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1326355/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527070345134080 |
|---|---|
| author | Lauri Mäkelä Anssi Pétas Arto Mikkola Harri Visapää |
| author_facet | Lauri Mäkelä Anssi Pétas Arto Mikkola Harri Visapää |
| author_sort | Lauri Mäkelä |
| collection | DOAJ |
| description | IntroductionThis retrospective study aims to evaluate the long-term efficacy and urinary toxicity of LDR-brachytherapy for localized prostate cancer.Materials and methods235 primary prostate cancer patients treated with LDR-brachytherapy and subsequently followed up in our center were included in this study. Biochemical relapse free survival (bRFS), overall survival (OS), and cancer-specific survival (CSS) were evaluated. Additionally, the incidence of late urinary complications was recorded.ResultsMedian follow-up time was 11,6 years. 181 patients (77%) were classified as low-risk patients, while 52 patients (22,1%) were intermediate risk. The overall bRFS was 83,8% at 5 years and 72,4% at 10 years. 5- and 10-year OS were 97,8% and 87,8% respectively. There was no statistically significant difference in bRFS or OS between different risk groups. The rate of late urinary complications was 8,9%. Volume of prostate had a statistically significant effect on bRFS, as smaller prostate volumes led to worse bRFS.ConclusionsThis retrospective study shows that LDR brachytherapy is an effective treatment for low- and intermediate risk prostate cancer patients with relatively low but still significant risk of late urinary complications. |
| format | Article |
| id | doaj-art-fd8cb784ca4447f1b0d5dfb343374103 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-fd8cb784ca4447f1b0d5dfb3433741032025-01-16T06:10:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.13263551326355Long-term outcomes of LDR-brachytherapy for localized prostate cancerLauri Mäkelä0Anssi Pétas1Arto Mikkola2Harri Visapää3Comprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, FinlandDepartment of Urology , University of Helsinki and Helsinki University Hospital, Helsinki, FinlandDepartment of Urology , University of Helsinki and Helsinki University Hospital, Helsinki, FinlandComprehensive Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, FinlandIntroductionThis retrospective study aims to evaluate the long-term efficacy and urinary toxicity of LDR-brachytherapy for localized prostate cancer.Materials and methods235 primary prostate cancer patients treated with LDR-brachytherapy and subsequently followed up in our center were included in this study. Biochemical relapse free survival (bRFS), overall survival (OS), and cancer-specific survival (CSS) were evaluated. Additionally, the incidence of late urinary complications was recorded.ResultsMedian follow-up time was 11,6 years. 181 patients (77%) were classified as low-risk patients, while 52 patients (22,1%) were intermediate risk. The overall bRFS was 83,8% at 5 years and 72,4% at 10 years. 5- and 10-year OS were 97,8% and 87,8% respectively. There was no statistically significant difference in bRFS or OS between different risk groups. The rate of late urinary complications was 8,9%. Volume of prostate had a statistically significant effect on bRFS, as smaller prostate volumes led to worse bRFS.ConclusionsThis retrospective study shows that LDR brachytherapy is an effective treatment for low- and intermediate risk prostate cancer patients with relatively low but still significant risk of late urinary complications.https://www.frontiersin.org/articles/10.3389/fonc.2024.1326355/fullprostate cancerLDRbrachytherapyradiotherapylong term outcomes |
| spellingShingle | Lauri Mäkelä Anssi Pétas Arto Mikkola Harri Visapää Long-term outcomes of LDR-brachytherapy for localized prostate cancer Frontiers in Oncology prostate cancer LDR brachytherapy radiotherapy long term outcomes |
| title | Long-term outcomes of LDR-brachytherapy for localized prostate cancer |
| title_full | Long-term outcomes of LDR-brachytherapy for localized prostate cancer |
| title_fullStr | Long-term outcomes of LDR-brachytherapy for localized prostate cancer |
| title_full_unstemmed | Long-term outcomes of LDR-brachytherapy for localized prostate cancer |
| title_short | Long-term outcomes of LDR-brachytherapy for localized prostate cancer |
| title_sort | long term outcomes of ldr brachytherapy for localized prostate cancer |
| topic | prostate cancer LDR brachytherapy radiotherapy long term outcomes |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1326355/full |
| work_keys_str_mv | AT laurimakela longtermoutcomesofldrbrachytherapyforlocalizedprostatecancer AT anssipetas longtermoutcomesofldrbrachytherapyforlocalizedprostatecancer AT artomikkola longtermoutcomesofldrbrachytherapyforlocalizedprostatecancer AT harrivisapaa longtermoutcomesofldrbrachytherapyforlocalizedprostatecancer |